Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis

Current Medical Research and Opinion

Volumn 24, Issue 6, 2008, Pages 1569-1575

  McCormick, Clare ^a   Caballero, Armando ^a   Tang, Aihua ^a   Balzli, Charles ^a   Song, Jenny ^b   O'Callaghan, Richard ^a,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b Health Cruiser Consulting   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Antibiotic; Dexamethasone; Keratitis; Pseudomonas; Tobramycin

Indexed keywords

DEXAMETHASONE PLUS TOBRAMYCIN; XANTHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; KERATITIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; SCORING SYSTEM; SLIT LAMP;

ANIMALS; ANTI-BACTERIAL AGENTS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; EYE INFECTIONS, BACTERIAL; KERATITIS; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; RANDOM ALLOCATION; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 46449127083     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802079877     Document Type: Article

References (28)

1. Notivol R, Amin D, Whitling A, et al. Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients: prospective, randomized, double-masked, two-arm, parallel group, placebo-controlled, multicentre study. Clin Drug Investig 2004;24:523-33
2. Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramacidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled parallel-group study. Clin Ther 2004;26:1274-85
3. Camesasca FI, Bianchi C, Beltrame G, et al. Control of inflammation and prophylaxis of endophthalmitis after cataract surgery: a multicenter study. Eur J Ophthalmol 2007;17:733-42
4. Russo S, Papa V, Di Bella A, et al. Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. Eye 2007;21:58-64
5. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo- keratoconjunctivitis. Adv Ther 2007;24:60-7
6. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008;24:287-96
7. Meseguer G, Buri P, Plazonnet B, et al. Gamma scintigraphic comparison of eye drops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 1996;12:481-8
8. Albasini M, Ludwig A. Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms. Farmaco 1995;50:633-42
9. Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in an ophthalmic liquid dosage form: rheological characterization of the interaction with mucin. J Pharm Sci 2002;91:1117-27
10. Scoper SV, Kabat AG, Owen GR, et al. Ocular distribution, bactericidal activity, and settling characteristics of TobraDex® ST compared with TobraDex® ophthalmic suspension. Adv Ther 2008: published online 29 February 2008, doi:10.1007/s12325-008-0019-9
11. Umamaheswara Reddy C, Arun A, et al. Polymeric drug based on sulfanilamide: synthesis, antimicrobial and drug releasing studies. J Pharm Pharmacol 2007;59:1207-13
12. Grare M, Mourer M, Fontanay S, et al. In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant gram-negative and gram-positive bacteria. J Antimicrob Chemother 2007;60:575-81
13. Hobden JA, Hill JM, Engel LS, O'Callaghan RJ. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. Antimicrob Agents Chemother 1993;37:1856-9
14. Guzek JP, Chacko D, Kettering JD, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea 1994;13:500-4
15. O'Callaghan RJ, Engel LS, Hobden JA, et al. Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci 1996;37:534-43
16. O'Callaghan RJ, McCormick CC, Caballero AR, et al. Age-related differences in rabbits during experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci 2007;48:5125-31
17. Dajcs JJ, Thibodeaux BA, Girgis DO, O'Callaghan RJ. Corneal virulence of Staphylococcus aureus in an experimental model of keratitis. DNA Cell Biol 2002;21:375-82
18. Engel LS, Callegan MC, Hobden JA, et al. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 1995;14:229-34
19. Engel LS, Hobden JA, Moreau JM, et al. Pseudomonas deficient in protease IV has significantly reduced corneal virulence. Invest Ophthalmol Vis Sci 1997;38:1535-42
20. Andrean SD, Cochrane R, Reilly CD, Mannis MJ. Infectious keratitis after astigmatic keratotomy in penetrating keratoplasty: review of three cases. Cornea 2005;24:626-8
21. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology 2007;114:1622-9
22. Leibowitz HM, Kupferman A, Stewart RH, Kimbrough RL. Evaluation of dexamethasone acetate as a topical ophthalmic formulation. Am J Ophthalmol 1978;86:418-23
23. Hobden JA, Engel LS, Hill JM, et al. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 1993;12:469-73
24. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;doi:10.1136/bjo.2007.132621
25. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55
26. Clark AF, Wilson K, de Kater AW, et al. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci 1995;36:478-89
27. Leibowitz HM, Kupferman A. Topically administered corticosteroids: effects on antibiotic treated bacterial keratitis. Arch Ophthalmol 1980;98:1287-90
28. Davis SD, Sarff LD, Hyndiuk RA. Corticosteroid in experimentally induced Pseudomonas keratitis: failure of prednisolone to impair the efficacy of tobramycin and carbenicillin therapy. Arch Ophthalmol 1978;96:126-8